note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
note ||| DOI 10.1007/s10549-009-0339-8 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_yes xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
note ||| PRECLINICAL STUDY |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
title ||| Sox17, the canonical Wnt antagonist, is epigenetically inactivated |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_largest0 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
title ||| by promoter methylation in human breast cancer |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest0 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
author ||| De-Yuan Fu � Zhi-Min Wang � Li-Chen � |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
author ||| Bei-Lan Wang � Zhen-Zhou Shen � Wei Huang � |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
author ||| Zhi-Ming Shao |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
note ||| Received: 25 September 2008/Accepted: 3 February 2009 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
note ||| � Springer Science+Business Media, LLC. 2009 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| Abstract SRY-box 17 (Sox17) is a transcription factor |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
bodyText ||| which involved in a variety of developmental processes |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| and can act as an antagonist of canonical Wnt/fl-catenin |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| signaling pathway. However, the relationship between |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| Sox17 gene expression, methylation status, and fl-catenin |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| in breast cancer has not been established. Here we report |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| that the expression level of Sox17 mRNA was dramatically |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| decreased in five different breast cancer cell lines and 23 of |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| 31 primary breast tumor samples, which significantly cor- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| related with its methylation status. After treated with 5-aza- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| 2'-deoxycytidine (5-aza-dC, a demethylation agent), the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| expression levels of Sox17 mRNA and protein were |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| obviously increased. Restored expression of Sox17 by |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| 5-aza-dC treatment decreased the expression level of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| fl-catenin in breast cancer cell lines. Furthermore, small |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| interfering RNA (siRNA)-mediated knockdown of Sox17 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| in SKBR-3 and Bacp-37 cells enhanced fl-catenin expres- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| sion. In 31 paired tissue samples, a significant difference |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| between the expression level of Sox17 and fl-catenin was |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| also observed (P &lt; 0.001). Clinically, Sox17 methylation |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| was detected in 74.3% breast tumors (84/113) and 31.9% |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| (36/113) paired normal tissues, respectively (P &lt; 0.0001). |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| Sox17 methylation was also associated with tumor stage |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
note ||| De-Yuan Fu and Zhi-Min Wang have contributed equally to this work. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
author ||| D.-Y. Fu • Li-Chen • Z.-Z. Shen • Z.-M. Shao (®) |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
affiliation ||| Department of Breast Surgery, Cancer Hospital/Cancer Institute, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
affiliation ||| Breast Cancer Institute, Fudan University, 399 Ling-Ling Road, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
affiliation ||| Shanghai 200032, China |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
email ||| e-mail: zhimingshao@yahoo.com |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
author ||| Z.-M. Wang • B.-L. Wang • W. Huang (®) |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
affiliation ||| Chinese National Human Genome Center at Shanghai, 250 Bi |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
affiliation ||| Bo Road, Shanghai 201203, China |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
email ||| e-mail: huangwei@chgc.sh.cn |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| (P = 0.028) and lymph node metastasis (P = 0.013). |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
bodyText ||| These findings indicate that silencing of Sox17 due to |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| promoter hypermethylation is a frequent event and may |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| contribute to aberrant activation of Wnt signaling in breast |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| cancer. Sox17 may be a valuable biomarker for the study of |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
bodyText ||| breast cancer carcinogenesis and progression. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
keyword ||| Keywords Breast cancer • Sox17 • DNA methylation • |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_header
keyword ||| Wnt signaling |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_header
sectionHeader ||| Introduction |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Breast cancer is the second most frequent cause of cancer |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| death among women [1]. Although considerable progress |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in both the diagnosis and adjuvant therapies has been |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| made, the pathogenesis of the disease remains poorly |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| understood. In the past few years, it has been recognized |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| that the silencing of tumor related genes associated with |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| promoter hypermethylation is a common feature in human |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer and serves as an alternative mechanism for loss of |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumor suppressor gene function [2–4]. Numerous genes, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| including those involved in DNA damage repair, cell cycle |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| regulation, cell adhesion, and cell signal transduction |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| [5, 6], have been found to be hypermethylated during the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| development and progression of breast cancer. The |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| hypermethylation of these genes plays important roles in |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| carcinogenesis and tumor progression of breast cancer. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17, a member of the Sox (Sry-related high mobility |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| group box) family of transcription factors, is conserved in |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| many species and participates in a variety of biological |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| activities and developmental processes [7–10]. A number |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of Sox genes are amplified or upregulated in different |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumors samples and cell lines which suggested they played |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| an important role in human tumorgenesis [11]. Sox17 gene |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| has been reported to be involved in oligodendrocyte |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| development [12], vascular development [13] and forma- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion of definitive endoderm [14, 15]. Furthermore, Sox17 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| has an important effect on the regulation of stem cell |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| function [16–18], and can act as a negative regulation |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| factor of fl-catenin/TCF transcription activity in the Wnt |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| signal transduction pathway [19–22]. Although several |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| studies have shown that Sox17 might also play a role in |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| human carcinogenesis [19, 20, 23], its potential role in |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| human breast cancer has not been clarified. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The Wnt signaling pathway is involved in many |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| developmental processes and tumorigenesis [24, 25]. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Usually, the pathway operates by stabilizing and accumu- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| lating of fl-catenin in the nucleus, where it interacts with |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| TCF/LEF transcription factors, leading to activation of |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| downstream target genes [26]. Although compelling evi- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dence indicates that activation of Wnt signaling plays an |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| important role in breast cancer [27, 28], the mechanism has |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| not been well understood. Recently, many Wnt pathway |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| antagonists, such as SFRPs (SFRP1, SFRP2 and SFRP5), |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| WIF-1 and Dkk-1, have been reported to be epigenetically |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| silenced in breast cancer [29–33], indicating that epigenetic |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| silencing of Wnt inhibitors might be an important mecha- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| nism underlying activating the Wnt pathway in breast |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Several members of the Sox gene family, such as Sox17, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| Sox3, Sox7 and Sox9, are structurally related to TCF/LEFs |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and have also been implicated in repressing the activity of fl- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| catenin [34–36]. In the case of Sox17, it can cooperate with |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| fl-catenin to regulate the transcription of endodermal genes |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in Xenopus embryos [22]. Depletion of Xenopus embryos of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| endogenous Sox17 protein results in the hyperactivation of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Wnt target genes [22]. Sox17 is also indispensable for the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| specification of cardiac mesoderm in embryonic stem cells |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| by inactivating the canonical Wnt pathway [18]. Further- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| more, knockdown of Sox17 resulted in the up-regulation of |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the Wnt target gene, while over-expression of Sox17 led to |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the opposite result [19, 20]. In colorectal cancer (CRC), |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox 17 also has a powerful capacity to suppress fl-catenin/T- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cell factor dependent transcription activity [20]. These |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| findings indicated that Sox17 may be one of important |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| antagonists of Wnt/fl-catenin signaling in diverse develop- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| mental and disease contexts. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Previous study revealed that Sox17 mRNA was almost |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| undetectable in 66 human primary tumors derived from |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| various tissues [37]. Zhang et al. thought that the down- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| regulated expression of Sox17 gene in CRC cells was due |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to its promoter hypermethylation, and methylation-depen- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dent silencing of Sox17 could be detected in 100% of CRC |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cell lines, almost 100% CRC tissues, 80% esophageal |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer and 50% non-small cell lung cancer tissues [20]. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Moreover, restored expression of Sox17 could decrease the |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| proliferation rates of colon cancer cells, suggesting a |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| potential role in tumor suppression. Recently, our analysis |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| by DNA methylation microarray demonstrated that Sox17 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was also one of most significant hypermethylated genes in |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast cancer. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In this study, we performed a parallel expression and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| promoter methylation analysis in breast cancer cell lines, |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumor samples to further investigate the expression profile, |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation status and clinical significance of Sox17 in |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast cancer. In addition, the correlation between Sox17 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and fl-catenin expression levels was also evaluated to |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| investigate the potential role of Sox17 in the activation of |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Wnt signaling pathway in breast cancer. Our data indicate |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| that silencing of Sox17 caused by promoter hypermethy- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| lation is a frequent event and may contribute to aberrant |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| activation of Wnt signaling in breast cancer. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| Materials and methods |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| Cell lines and 5-aza-2'-deoxycytidine treatment |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| Seven breast tumor cell lines ZR-75-30, MDA-MB-231, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| MDA-MB-435s, Bacp-37, MCF-7, T47D and SK-BR-3, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were obtained from American type culture collection |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (ATCC, Manassas, VA). Cell lines ZR-75-30, Bacp-37, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| MCF-7, T47D, SK-BR-3 and cell lines MDA-MB-231, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| MDA-MB-435s were maintained in DMEM and Leibo- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| vitz’s L-15 medium, respectively. Both medium were |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| supplemented with 10% fetal bovine serum (GIBCO), |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 100 U/ml penicillin, and 100 mg/ml streptomycin at 37�C |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in 5% CO2 humidified atmosphere. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Cells were seeded at a density of 5 x 104 cells/cm2 in a |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| six-well plate, following a 24-h incubation, fresh culture |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| medium with or without the demethylating agent 5-aza-2'- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| deoxycytidine (Sigma–Aldrich Co. Ltd.) was added to a |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| final concentration of 5 lmol/l, and incubated for another |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 48 h. 5-aza-dC (Sigma) was freshly prepared as 2 mmol/l |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| stock solution in PBS before use. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Human breast tumor and paired normal tissue |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| Between April and June 2006, 113 primary breast carci- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| nomas and paired normal tissue specimens, from which |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| RNA samples were available in 31 pairs of the samples, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were obtained from Cancer Hospital of Fudan University, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Shanghai, China. Immediately after resection, specimens |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were flashly frozen in liquid nitrogen and stored at —80°C. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The remaining tissue specimens were routinely processed |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for histopathological analyses. Pathological information, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| including histological tumor type, primary tumor size, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| axillary lymph nodal status, grade of the disease, estrogen |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and progesterone receptors status and HER2/neu expres- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sion status, was obtained. The mean age of the patients was |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| Table 1 Clinical characteristics of 113 patients with and without |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| Sox17 methylation |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
table ||| Clinical 	No.	Sox17 methylation status	Pa value |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| parameter |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Methylated,	Unmethylated, |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| n = 84 (74.3%)	n = 29 (25.7%) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Age (y) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| &lt;50	69	51 (73.9)	18 (26.1)	0.897 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| C50	44	33(75)	11 (25) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Tumor histology |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| IDC	100	75(75)	25 (25)	0.929 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| DCIS	13	9(69.2)	4(30.8) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Stage |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| 0–I	29	17 (58.6)	12 (41.4)	0.028* |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| II–IV	84	68 (81.0)	16 (19.0) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Tumor grade |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| I–II	70	54 (77.1)	16 (22.9)	0.990 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| III	22	17 (77.2)	5 (22.8) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Not known	21	13 (61.9)	8 (38.1) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Lymph node status |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Negative	71	47 (66.2)	24 (33.8)	0.013* |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Positive	42	37 (88.1)	5 (11.9) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| ER status	0.905 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Negative	73	54 (74.0)	19 (26.0) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Positive	40	30 (75.0)	10 (25.0) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| PR status	0.854 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Negative	64	48 (75.0)	16 (25.0) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Positive	49	36 (73.5)	13 (26.5) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| HER-2/neu status	0.356 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Negative	78	56 (71.8)	22 (28.2) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
table ||| Positive	35	28 (80.0)	7(20.0) |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
tableCaption ||| a P values are obtained from X2 test |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
tableCaption ||| * Statistically significant, P &lt; 0.05 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 49.1 years old (range 26–81 years old). Detailed clinico- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| pathologic parameters were listed in Table 1. This project |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| has been approved by the Scientific and Ethical Committee |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of the Cancer Hospital of Fudan University. All patients |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gave written informed consent permitting the use of their |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast tissue for research at the time specimens were |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| collected. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Gene expression analysis by RT-PCR and real-time |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| RT-PCR |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Total RNA was isolated with RNeasy Mini kit (Qiagen |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| GmbH, Hilden, Germany) and treated with DNase, accord- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ing to the manufacturer’s instructions. First-strand cDNA |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was synthesized with oligo-dT-primers (Promega, Madison, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| WI, USA). Sox17 specific primers used were 5'-AGTGAC |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| GACCAGAGCCAGAC-3' (forward) and reverse 5'-CCTT |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| AGCCCACACCATGAAA-3'. fl-catenin specific primers |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| used were 5'-GAAACGGCTTTCAGTTGAGC-3' (forward) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| and 5'-CTGGCCATATCCACCAGAGT-3' (reverse). Glyc- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| eraldehyde-3-phosphate dehydrogenase (GAPDH) served as |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| a control for RNA integrity and was amplified using primers: |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 5'-GAAGGTGAAGGTCGGAGTC-3' (forward) and 5'- GA |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| AGATGGTGATGGGATTTC-3' (reverse). PCR thermo |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| cycling conditions used are 1 cycle at 95�C for 15 min; 38 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cycles at 94�C for 30 s, 57�C for 30 s, and 72�C for 30 s; and |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| final extension at 72�C for 7 min. Following thermocycling, |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| reactions were analyzed by electrophoresis on 1.5% agarose |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gels followed by staining with ethidium bromide and directly |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| visualized under UV illumination. Real-time PCR reactions |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were carried out using the default PCR cycle on a sequence |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| detection system ABI Prism 7900 HT (Applied Biosystems), |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and amplified cDNA was detected by SYBR Green I dye |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Qiagen GmbH, Hilden, Germany). Dissociation curve |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| analyses were performed to confirm the specificity of the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| SYBR Green signals in each experiment. Data were analyzed |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| using ABI Prism 7900 SDS Software (Sequence Detection |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Systems 2.0; Applied Biosystems). Standard curves relating |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| initial template copy number to fluorescence and amplifi- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cation cycle were generated using the amplified PCR product |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| as a template, and were used to calculate mRNA copy |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| number in each sample. Ratios of the intensities of the target |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| genes and GAPDH signals were used as a relative measure of |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the expression level of target genes. Primer sequences of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17, GAPDH and fl-catenin for qRT-PCR analysis are |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| same as RT-PCR. To ensure experiment accuracy, Real-time |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| PCR assays were conducted in triplicate for each sample, and |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the mean value was used for calculation. For analysis of the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| matched breast tumor and normal samples, the abundance of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 and fl-catenin transcript in tumor tissues was defined |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| as one and the relative transcript abundance in normal ones |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was calculated accordingly. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Small interfering RNA (siRNA) transfection |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| Small interfering RNA-mediated knockdown of Sox17 or |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| fl-catenin were performed in SKBR-3 and Bacp37 cells. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 siRNAs (sc-38429), fl-catenin siRNAs (sc-29209) |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and control siRNAs (sc-44233) was obtained from Santa |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Cruz Biotechnology Inc. (Santa Cruz, CA). The siRNA |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was introduced into the cultured cells using lipofectamine |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 2000 reagent according to the manufacturer’s instructions. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| At 48 h after transfection, cells were harvested. Sox17 or |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| fl-catenin mRNA and protein levels were checked by qPCR |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and western blotting analysis, respectively. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Western blotting |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Total cell lysates were extracted from SKBR-3, Bcap37, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| MDA-MB-231, MDA-MB-435s and T47D cells, and |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| quantified by BCA Protein Reagent Kit (Pierce, Rockford, |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| IL). Primary antibodies of Sox17 (sc-20099), fl-catenin (sc- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 7199) and GAPDH (sc-25778) were obtained from Santa |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Cruz Biotechnology Inc. (Santa Cruz, CA). Forty micro- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| grams of protein were separated by 10% SDS–PAGE and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| then transferred to nitrocellulose membranes. Following |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| blocking, membranes were hybridized with primary anti- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| body overnight at 4�C and then hybridized with IRDye |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 700-conjugated anti-rabbit IgG secondary antibody |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Rockland, Gilbertsville, PA) in the dark for 1 h at room |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| temperature. The signals were detected using the Odyssey |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Imaging System (LI-COR Bioscience, Inc.) and analyzed |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with Odyssey software. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Genomic DNA extraction and sodium bisulfite |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| modification |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Genomic DNA was isolated from cells and tissues using |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| the DNeasy Kit (Qiagen, Hilden, Germany) and stored at |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| —20°C before use. DNA was modified with EZ DNA |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Methylation-Gold KitTM (ZYMO Research Co., Orange, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| CA) according to the manufacturer’s instruction. Briefly, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 0.5 �g denatured DNA was treated with sodium bisulfite at |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 98�C for 10 min and then 64�C for 2.5 h. Samples were |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| then applied to supplied columns, subjected to column |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| washing, desulfonation and re-washing, and then DNA was |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| subsequently eluted with 10 �l elution buffer. Generally, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 1 �l modified DNA was used in subsequent PCRs. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Bisulfite genomic sequencing |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| The genomic DNA fragment from —180 bp to +240 bp |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| (ATG, +1) of the Sox17 gene was amplified from sodium |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| bisulfate modificated DNA. The primers for BGS are 5'-GT |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| TTTGGGTAYGTTGTAGATTA-3' (forward) and 5'-CTT |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| AACCCACACCATAAAAAC-3' (reverse). The following |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| thermocycling conditions were used: 1 cycle at 95�C for |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| 15 min; 38 cycles at 94�C for 30 s, 58�C for 30 s, and 72�C |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for 30 s; and final extension at 72�C for 7 min. PCR products |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were purified with the Gel Extraction kit (Bionex), cloned |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| into pMD20-T Vector (TaKaRa, Madison, WI, USA), and |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| then transformed into E. coli strain DH10B. 10–15 colonies |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were selected to confirm the presence and size of the cloned |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| insert. Five positive clones for each sample were selected and |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| amplified using the vector’s universal primers (P2, 5'-GTA |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| AAACGACGGCCAGT-3', p4, 5'-AGAGGATAACAATT |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| TCACACAGGA-3'). After purification the sequence of PCR |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| product is analyzed using ABI 3730 DNA Sequencer |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| (Applied Biosystems). The methylation percentage for each |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sample was calculated as the number of methylated CpG |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dinucleotides from the total number of CpGs analyzed in all |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| positive clones. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Methylation specific PCR (MSP) |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| The primers for the methylated sequence of Sox17 gene |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| were 5'-GGAGATTCGCGTAGTTTTCG-3' (forward) and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| 5'-AACCCGACCATCACCGCG-3' (reverse). For unme- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| thylated sequence were 5'-GGAGATTTGTGTAGTTTT |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| TG-3' (forward) and 5'-AACCCAACCATCACCACA-3' |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| (reverse). Qiagen HotStarTaq DNA polymerase was used |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for PCR. Thermocycling conditions used were one cycle at |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 95�C for 15 min; 38 cycles at 94�C for 30 s, 59�C (for M |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| primer set) or 58�C (for U primer set) for 30 s, and 72�C for |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 30 s; and final extension at 72�C for 7 min. PCR products |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were loaded 2% agarose gels followed by staining with |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ethidium bromide and directly visualized under UV illu- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| mination. SssI-methylated DNA and whole-genome-ampli- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| fication (WGA) DNA of normal peripheral lymphocytes |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were used as positive and negative controls, respectively. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Statistical analysis |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Differences gene expression level in cell lines or tissues |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| was tested by Mann–Whitney U test. Gene expression |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| levels of paired samples were evaluated by the non-para- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| metric Wilcoxon Signed Ranks test. After grouping the |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation levels into two categories, associations were |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tested by the use of contingency tables and the calculation |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of X2 test was applied for the determination of significance |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of the association. All statistical tests are two sided, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| P &lt; 0.05 was considered to be significant. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| Results |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| Sox17 is a candidate for aberrant gene silencing |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| in breast cancer cells |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Promoter methylation often results in silencing of the gene |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| product and can be restored by demethylating agent 5-aza- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dC. Thus, we firstly evaluated the expression of the Sox17 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in a panel of breast cancer cell lines by RT-PCR. As shown |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in Fig. 1a, the expression of Sox17 was undetectable or |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| expressed at extremely low levels in five breast cell lines |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (ZR-75-30, MDA-MB-231, MDA-MB-435s, MCF-7 and |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| T-47D), in contrast, Sox17 was expressed in cell lines |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Bacp-37 and SK-BR-3 at higher level. After these cells |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were treated with the demethylating agent 5-aza-dC, the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| expression of Sox17 was dramatically reactivated, where |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the Sox17 previously showed none or low expression |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Fig. 1 a). |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To confirm and quantify the changes of Sox17 expres- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| sion, we conducted a qRT-PCR analysis in all 5-aza-dC |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| treated cell lines. A 48 h treatment with 5-aza-dC led to |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| significantly increase of Sox17 transcripts in these cell |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| lines compared with the untreated cells. Consistent with the |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| RT-PCR results, there was no significant change in Sox17 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| mRNA in 5-aza-dC treated Bacp-37 and SK-BR-3 cells |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Fig. 1b). |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| We further investigated the protein expression of Sox17 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| by western blots in four selected breast cancer cell lines |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| SK-BR-3, MDA-MB-231, T-47D and MDA-MB-435s. The |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| protein level of Sox17 was consistent with its mRNA levels |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| as represented by the results of RT-PCR and qRT-PCR |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Fig. 1 c). |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Silencing of Sox17 is associated with its promoter |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| CpG island hypermethylation |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The Sox17 gene is composed of two exons. Exon 1 encodes |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| the 5' untranslated region (5'VTR) of the Sox17 transcript |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and 5' coding region including the translational initiation |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| codon (ATG). Exon 2 encodes 3' coding region including |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the translational stop codon (TGA) and the 3' VTR of the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 transcript. We found that the 5' end of the Sox17 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| gene is unusually CG rich, and there is a CpG island |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| encompassing its transcription start site. Because aberrant |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cytosine methylation within CpG islands encompassing |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| both the 5' flanking region and the transcriptional start site |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| was commonly observed in cancer cell genomes [38, 39], |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| we then analyzed a 420 bp segment of this region |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (-180 bp to +240 bp; ATG, +1) which contains 48 CpG |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dinucleotides and meets the criteria of a CpG island |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Fig. 2). |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To analyze the methylation status in details, we carried |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| out bisulfite sequencing in all the above cell lines. Direct |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequencing of five individual clones of each cell line |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| showed that densely methylated CpG sites were detected in |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| MD-MB-231, MD-MB-435s, MCF-7, ZR-75-30 and T47D |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cell lines, while&lt;10% methylated CpG sites were found in |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Bcap-37 and SK-BR-3 cell lines (Fig. 3a, b). |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To further confirm the sequencing results, we designed a |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| set of methylation specific PCR (MSP) primers in this |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| region to detect methylation status of these breast cell lines. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The results showed that Sox17 was methylated in all |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| silenced cell lines MD-MB-231, MD-MB-435s, MCF-7, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ZR-75-30 and T47D. In contrast, there was no methylation |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| detected in Sox17-expressing cell lines Bacp-37 and |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| SK-BR-3 (Fig. 3c). After treated with 5-aza-dC, the unme- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| thylated band in MCF-7 and T47D was detected (Fig. 3d). |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| DNA methylation suppress Sox17 expression |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| in primary breast tumors |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To determine whether epigenetic silencing of the Sox17 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| gene also occurs in primary breast tumors, we analyzed |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 expression in 31 paired breast tumor samples |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and corresponding normal breast tissues. We observed |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Fig. 1 RT-PCR and qRT-PCR analysis of the Sox17 gene expression |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| in breast cancer cell lines a RT-PCR analysis of Sox17 mRNA |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| expression in seven breast cancer cell lines (MDA-MB–231, MDA- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| MB–435s, Bacp-37, T47D, ZR-75-30, MCF-7 and SK-BR-3). Sox17 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| gene expression was induced in five breast cancer cell lines (MDA- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| MB-231, MDA-MB-435s, MCF-7, Bacp37 and T47D) after treating |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| with DNA demethylating drug 5-aza-dC (5 �mol/l) for 48 h. GAPDH |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| was amplified as an internal control. DW, distilled water, “+” and |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| ‘‘-”denote with and without 5-aza-dC treatment, respectively; b |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 mRNA expression analysis by qRT-PCR in seven breast cell |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| lines either not-treated or treated with 5 �mol/l 5-aza-dC. GAPDH |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| was used to normalize gene expression levels for each cell line. The |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| representative results, conducted in triplicates, are shown as |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| mean f SD. “*”Denotes statistical significance at P &lt; 0.05 com- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| pared to 0 h values; c Western blot analysis of Sox17 protein in four |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| selected breast cancer cell lines (SK-BR-3, MDA-MB-231, T47D and |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| MDA-MB-435s). GAPDH was used as a control for the different cell |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| lysates. “+” and “-”denote with and without 5-aza-dC treatment, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| respectively |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| detectable Sox17 mRNA transcripts in most normal breast |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| samples compared to tumor samples. The representative |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| results of RT-PCR were shown in Fig. 4a. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| By using qRT-PCR, we found that 23 out of 31 (74.2%) |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| breast tumors exhibited a reduced expression levels of |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| Fig. 2 Genomic architecture of the human Sox17 gene The UCSC |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| genome browser was used to search the March 2006 assembly of the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| human genome database to examine the Sox17 locus. a Location of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| the Sox17 gene in human chromosome 8 (ch8 q11.23); b Exon/intron |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| structure of the human Sox17 gene. Picture is the relative location of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| the two coding exons, the translational start codon (ATG); c Structure |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| of the 5' end of the Sox17 gene. Graph of percent guanine (G) and |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| cytosine (C) nucleotides across this region, location of the 48 CpG |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| Sox17 compared to the corresponding normal breast tissue |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| (relative gene expression T/N &lt; 0.5). A significant differ- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ence between tumor tissues and the corresponding normal |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast tissues was observed (Wilcoxon Signed Ranks Test, |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| P &lt; 0.005, Fig. 4b). |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Subsequently, we examined Sox17 methylation status of |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| this panel of matched samples using MSP. Aberrant |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation was detected in 25 of 31 (80.6%) tumors, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| which was more frequent than that in the paired normal |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tissues (9 of 31, 29.0%; P &lt; 0.001) (Fig. 4c). In 25 cases |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of methylated tumor samples, 21 (84.0%) showed a lower |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 expression which indicated a correlation between |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| CpG island methylation and transcriptional silencing. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Furthermore, we found the expression ratio between nor- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| mal tissues and tumor tissues was significantly different in |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the methylated and unmethylated tumor tissues (Mann– |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Whitney U test, P = 0.0034) (Fig. 4d). |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To confirm our MSP results and determine the methyl- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| ation extent of Sox17 promoter in primary breast tumors |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| dinucleotides within this region, and boundaries of the CpG island |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| (shaded region). Note also exon 1 and the transcriptional start codon |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (ATG) of the Sox17 gene; d Details of the Sox17 promoter region |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequence. The bisulfite sequencing PCR primers are presented in red, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| italics and bold. The MSP primers were highlighted in blue with |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| underline. There are 48 CpG sites in this region, and the CpG sites |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| were numbered. The first letter of the transcriptional start codon |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (ATG) is counted as ?1 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| versus paired normal tissue, we performed bisulfite |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| sequencing on one selected paired samples. We observed |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| hypermethylation of the majority of the CpG dinucleotides |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (85.4% methylation) within the region of the Sox17 pro- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| moter in tumor sample, whereas only a low-level of CpG |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation (5.8%) was in paired normal tissue (Fig. 4e). |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Therefore, this result further supported the notion that |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| promoter methylation of Sox17 was predominant in breast |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer samples but not in normal tissues. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 methylation in primary breast carcinomas |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| is associated with clinicopathologic parameters |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To ascertain how commonly this epigenetic event occurs in |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| breast cancer and its potential clinical significance, we |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| conducted MSP analysis in additional 82 pairs of patient- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| matched breast tumor and normal tissue samples. Together |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with the previous 31 pairs of samples, Sox17 CpG islands |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| hypermethylation was detected in 84 (74.3%) tumor |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| Fig. 3 Methylation status of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| Sox17 gene promoter in breast |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cancer cell lines. a Methylation |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| patterns of individual bisulfite- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| sequenced clones of the Sox17 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| promoter in breast cell lines. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Five clones from each sample |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| were bisulfite sequenced to |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| obtain a representative sampling |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| of methylation patterns, CpG |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| dinucleotides are represented in |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| squares (■ methylated |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cytosines, ❑ unmethylated |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cytosines). Names of the cell |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| lines and the percentage of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| methylation of the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| corresponding cell line are |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| indicated on the left and right |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| side, respectively; b Illustration |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| of representative examples of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| the chromatograms of CpG sites |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| from 16th CpG dinucleotide to |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| 23rd CpG dinucleotide of the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 bisulphite sequencing |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| fragment; c MSP analysis of the |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 gene in seven breast |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cancer cell lines without 5-aza- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| dC treatment. The promoter |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| region of the Sox17 gene was |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| methylated in five cell lines |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| (ZR-75-30, MDA-MB-231, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| MDA-MB-435s, MCF-7 and |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| T47D). Lanes labeled M and U |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| denote products amplified by |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| primers recognizing methylated |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| and unmethylated sequence, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| respectively. PC, positive |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| control, NC, negative control, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| DW, distilled water; d MSP |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| analysis of the Sox17 gene in |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| four breast cancer cell lines |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| (Bacp-37, MCF-7, T47D and |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| SK-BR-3) with 5-aza-dC |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| treatment |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_none xmlPic_no xmlTable_yes xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| Fig. 4 Correlation analysis of |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
figureCaption ||| Sox17 expression and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| methylation in breast cancers. a |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| RT-PCR analysis of Sox17 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| mRNA expression in breast |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cancer samples (T) and matched |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| normal tissue (N). GAPDH was |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| amplified as an internal control; |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| b Box plot illustration for the |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| expression of Sox17 gene in 31 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| breast cancer and paired normal |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| breast tissue samples. In |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| primary breast tumors, Sox17 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| expression is significantly |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| reduced compared to the normal |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| breast tissue (Wilcoxon Signed |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Ranks Test, P &lt; 0.05). |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Horizontal lines, group |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| medians; boxes, 25–75% |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| quartiles, range, peak and |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| minimum; c Representative |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| results of MSP analysis of |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 promoter methylation |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| status in 12 of 31 primary breast |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cancers (T) and matched normal |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| breast tissue (N). U, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| unmethylated; M, methylated; d |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Correlation between Sox17 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| promoter methylation status and |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| gene expression levels by qRT- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| PCR analysis of Sox17 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| expression in the 31 breast |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cancers and matching normal |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| breast tissues. Methylation |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| status was analyzed by MSP. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| The bar represents ratio of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 mRNA expression levels |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| in normal and tumor tissue. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 expression levels |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| correlated with the methylation |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| status of the gene (P = 0.0034, |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Mann–Whitney U test). e |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Bisulfite sequencing analysis of |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| a selected matched breast tumor |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| and normal breast tissue |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| (sample brc13). (1) Result of |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| sequence analysis of five |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| independent clones for each |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| sample (■ methylated |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cytosines, ❑ unmethylated |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cytosines). (2) Illustrates |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| representative examples of the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| chromatograms of CpG sites |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| from the 14th CpG dinucleotide |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| to the 22nd CpG dinucleotide of |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| the Sox17 bisulfite sequencing |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| fragment |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| samples and 36 (31.9%) patient-matched normal tissue |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| of all the 113 patients (P &lt; 0.001). The relationship |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| between Sox17 methylation and various clinicopathologi- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cal parameters was shown in Table 1. A significant |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| association was found between Sox17 methylation and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumor stage (81.0% methylated in stage II–IV tumors vs. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 58.6% in stage 0–I tumors, P = 0.028). Methylation level |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was significantly lower in tumors with node-negative |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancers than that in node-positive tumors (66.2% methyl- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ated in node-negative cancer vs. 88.1% in node-positive |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumors, P = 0.013). No significant correlation was |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| observed between Sox17 methylation and other parameters |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| such as age at diagnosis, tumor histology, ER/PR status or |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| HER-2/neu status. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Down-regulation of Sox17 by methylation may |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| upregulate the expression levels of fl-catenin |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| in breast cancer |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Several studies have demonstrated that Sox17 can |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| antagonize the canonical Wnt signaling pathway by |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| interacting with fl-catenin. Here we showed that Sox17 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was down-regulated by promoter methylation in breast |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer cell lines and tissues. Moreover, the expression of |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 could be reversed by the treatment with 5-aza-dC, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| we hypothesized that down-regulation of Sox17 may |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| have some effects on the expression of fl-catenin. We |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| therefore examined the relationship between expression |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| levels of Sox17 and fl-catenin in breast cancer cell lines. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In contrast to Sox17, the expression level of fl-catenin |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| presented a declining trend after treated with 5-aza-dC |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| for 48 h in both mRNA and proteins levels, respectively |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (Fig. 5a, b). |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| To further test our hypothesis, we performed siRNA |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| knockdowns of Sox17 or fl-catenin in two normal Sox17 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| expression breast cancer cell lines SKBR-3 and Bacp37. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Quantitative RT-PCR results confirmed that mRNA level |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of fl-catenin was significantly increased in cells transfected |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with Sox17 siRNAs. Western blot analysis showed that the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| fl-catenin protein was also increased after siRNA knock- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| down of Sox17 mRNA. However, the Sox17 mRNA level |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was not dramatically changed by transfected these cells |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| with fl-catenin siRNAs (Fig. 5c, d, e). |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Subsequently, we performed a quantitative detection of |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| the expression levels of fl-catenin in 31 breast cancer |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| samples and paired normal tissues. We found a higher |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| expression of fl-catenin in 20 of 31 (64.5%) breast tumors |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| compared to the corresponding normal breast tissues |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (P &lt; 0.005, Fig. 5f). The expression ratio between tumor |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| samples and normal tissues was significantly different in |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| the Sox17 and fl-catenin (P &lt; 0.001, Fig. 5g). Therefore, |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| our results suggested that down-regulation of Sox17 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| by methylation could lead to the increased expression |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of fl-catenin, and the down-regulation of Sox17 by meth- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| ylation may be one of mechanisms that activates Wnt/fl- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| catenin pathway in breast cancer. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| Discussion |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_largest-1 xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| In present study, we showed that Sox17 plays an important |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| role in breast cancer through a comprehensive analysis of |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 in breast cancer cell lines and primary tumors. We |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| found the expression level of Sox17 was significantly |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| decreased in five of seven breast cancer cell lines and could |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| be remarkably increased by the treatment with demethy- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| lating agent 5-aza-dC. These results demonstrate that |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 is transcriptionally silenced by epigenetic inactiva- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion in the breast cancer cell lines. Furthermore, bisulfite |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| sequencing and MSP detection also revealed that the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation status of the CpG islands in Sox17 promoter |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| was strongly correlated with its expression levels. Consis- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tently, in paired breast samples, we also observed a reduced |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| level of Sox17 expression in most of tumor tissues, which |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| showed a correlation between methylation and transcrip- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tional silencing. Our results clearly indicate that epigenetic |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| silencing of the Sox]7 gene is a common event in breast |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer. |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In about 74.3% of the 113 paired breast cancer tissues, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| the Sox]7 gene was found to be hypermethylated, which is |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| distinct to normal tissues. This indicated that epigenetic |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| silencing of Sox17 is not only a frequent and cancer-spe- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cific event in human breast cancer but also it might |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| prospectively act as a marker in distinguishing malignant |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast tissues from nonmalignant samples. Although Sox17 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation was also detected in normal tissue, there was |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| much more significant difference in stage II–IV than in stage |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 0–I tumors, suggesting this epigenetic aberration is an early |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| event in breast tumor initiation and contributed to the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| acquisition of an invasive cellular phenotype during breast |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer progression. Moreover, the significant correlation |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| between Sox17 methylation and lymph node metastases |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| further supported the important role of Sox17 in breast |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer progression. A recent study has revealed that |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| hypermethylation of Sox17 can be detected in CRC, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| esophageal squamous cancers and non-small cell lung can- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cer with a highly frequency [20]. Combined with the |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| findings in our study, it strongly implied that hypermethy- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| lation of Sox17 may be a common phenomenon in many |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| human malignancies, and epigenetic silencing of this gene |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| may contribute to a widespread significance for tumor |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| suppression. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| The fl-catenin is a key effector in the Wnt signaling |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| pathway [40]. In breast cancer, aberrant subcellular local- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ization of fl-catenin has been frequently observed and |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| associated with poor clinical outcome [28, 41–43]. Unlike |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| t Fig. 5 Correlation between Sox 17 and fl-catenin expression in breast |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| cancer cell lines and tissues. a fl-catenin mRNA expression was |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| analyzed by qRT-PCR in seven breast cell lines not-treated or treated |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| with 5 �mol/l 5-aza-dC for 48 h. The representative results, con- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| ducted in triplicates, are shown as mean f SD. “*”Denotes |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| statistical significance at P &lt; 0.05 compared to 0 h values; b Western |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| blot analysis of fl-catenin protein in four selected breast cancer cell |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| lines (SK-BR-3, MDA-MB-231, T47D and MDA-MB-435s). GAP- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| DH is shown as a control for the different cell lysates. “+” and “-”denote with and without 5-aza-dC treatment, respectively; c, d qRT- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| PCR assay was performed in Bcap-37 (c) and SKBR-3 (d) after |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
figureCaption ||| transfection of siRNAs targeting Sox17 or fl-catenin. Experiments |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| were done in triplicate, and values indicate means f SD; e Western |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| blotting of whole cell lysates extracted from SKBR-3 and Bcap-37 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| cells transfected with Sox17 and fl-catenin siRNAs. GAPDH was |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| used as a control for the different cell lysates. “C”, control siRNA; |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| “S”, Sox17 siRNA; “fl”, fl-catenin siRNA; f Box plot illustration for |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| the expression of fl-catenin gene in 31 breast cancer and paired |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| normal breast tissue samples. In primary breast tumors, fl-catenin |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| expression is significantly higher compared to normal breast tissue |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| (Wilcoxon Signed Ranks Test, P &lt; 0.005). Horizontal lines, group |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| medians; boxes, 25–75% quartiles, range, peak and minimum; g Real- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| time PCR analysis of Sox17 mRNA and fl-catenin expression in 31 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| matched pairs of normal and tumorous breast tissue. The ratio of the |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| expression in tumor and normal was significant difference between |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Sox17 (gray bars) and fl-catenin (black bars) (P &lt; 0.001, Mann– |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
figureCaption ||| Whitney U test) |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| colorectal and other types of cancer, mutations of Wnt |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| pathway components were surprisingly rare in breast can- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cer [44]. However, several antagonists have been reported |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| to be frequently hypermethylated in breast cancer [29–33], |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| which indicated that epigenetic silencing of these Wnt |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| inhibitors might represent the mechanistic link between |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| active Wnt signaling and the increasing risk of breast |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer. Several lines of evidence have shown that Sox17 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| can act as an antagonist in Wnt signaling pathway [16–22]. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 can antagonize the Wnt pathway by promoting the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| degradation of fl-catenin and TCF/LEF proteins in a |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| GSK3fl-independent manner, while the reduced Sox17 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| levels have an opposite effect and could result in the hy- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| peractivation of Wnt target genes [19–21]. Thus, aberrant |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| methylation of Sox17 might contribute to activation of Wnt |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| signaling pathway in breast cancer. Our current study |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| showed that, in contrast to Sox17, the expression of fl- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| catenin was decreased after being treated with 5-aza-dC in |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast cancer cell lines, and was significantly higher in |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumors than in paired normal tissues. Down-regulation of |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 by specific siRNA silencing in two normal Sox17 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| expression cell lines SKBR-3 and Bacp37 also showed that |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| decrease of Sox17 expression could increase the expression |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| levels of fl-catenin. Therefore, our results suggest that |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 may regulate the expression of fl-catenin and loss of |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 expression may be one of the reasons that lead to an |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| increase the expression of fl-catenin, which, in turn, pro- |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| motes activation of Wnt signaling in breast cancer. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In human breast cancer, other Wnt antagonists, such as |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_new
bodyText ||| SFRP1 , SFRP2, SFRP5, WIF-1, and DKK-1 [29–33], have |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| been proved to be down-regulated by promoter hyperme- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| thylation. Functionally, all these antagonists act at the level |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of the cell membrane to prevent ligand–receptor interac- |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tions [45]. However, different from those Wnt antagonists, |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Sox17 inhibits Wnt signaling at the level of the nuclear |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| complex between fl-catenin and TCF [19–21]. Therefore, |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| epigenetic silencing of Sox17 gene may result in activating |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Wnt signaling and promoting the tumor initiation and |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| progression in an independent or complementary manner |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (together with the epigenetic inactivation of other Wnt |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| inhibitors). For this reason, we could add Sox17 to the list |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of DNA hypermethylated Wnt antagonist genes in breast |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer. On the other hand, the epigenetic inactivation of |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Wnt antagonist genes can be generally implicated in |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| aggressiveness features and clinical prognosis in breast |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| cancer. For example, the loss of SFRP-1 is an independent |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| indicator of poor survival [29], and epigenetic inactivation |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| of the SFRP-5 gene is associated with unfavorable prog- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| nosis [31]. Meanwhile, studies have also revealed that the |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| restoration of Wnt antagonist gene expression by demeth- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| ylation reagents could induce downregulation of |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| downstream-activated genes of Wnt pathway and inhibit |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tumor growth rate [19, 20, 29, 31]. Thus, the specific res- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| toration of Sox17 gene expression by demethylating drugs, |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| which can also affect on other Wnt antagonist genes, could |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| be applied as a new and effective therapeutic strategy to |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| improve the prognosis of breast cancer. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| In summary, our findings indicate that epigenetic sup- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| pression of Sox17 is a frequent event inhuman breast cancer. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| This frequently aberrant epigenetic event might be impor- |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tant in the development and progression of breast cancer, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| and might be served as a valuable epigenetic biomarker for |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| breast cancer detection, prognosis and/or treatment. Our |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| results demonstrate the biological significance and clinical |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| relevance of this gene to human breast cancer. |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Acknowledgments The authors thank the studied patients for their |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
bodyText ||| willingness to cooperate with our study. This research was supported in |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| part by the grants from the National Basic Research Program of China |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| (2006CB910501, 2004CB518605), National Natural Science Founda- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| tion of China (30371580, 30572109); Chinese National Natural |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| Science Fund for Distinguished Young Scholars (30625019); Shang- |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| hai Science and Technology Committee (03J14019, 06DJ14004, |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
bodyText ||| 06DZ19504). |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
sectionHeader ||| References |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_common xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| 1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| CA Cancer J Clin 57:43–66 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 2. Herman JG, Baylin SB (2003) Gene silencing in cancer in |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| association with promoter hypermethylation. N Engl J Med |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 349:2042–2054. doi:10.1056/NEJMra023075 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 3. Das PM, Singal R (2007) DNA methylation and cancer. J Clin |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Oncol 22:4632–4642. doi:10.1200/JCO.2004.07.151 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 4. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| 128:683–692. doi:10.1016/j.cell.2007.01.029 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
note ||| Breast Cancer Res Treat |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| 5. Szyf M, Pakneshan P, Rabbani SA (2004) DNA methylation and |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| breast cancer. Biochem Pharmacol 68:1187–1197. doi:10.1016/j. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| bcp.2004.04.030 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 6. Agrawal A, Murphy RF, Agrawal DK (2007) DNA methylation |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| in breast and colorectal cancers. Mod Pathol 20:711–721. doi: |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 10.1038/modpathol.3800822 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 7. Kamachi Y, Uchikawa M, Kondoh H (2000) Pairing SOX off: |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| with partners in the regulation of embryonic development. Trends |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Genet 16:182–187. doi:10.1016/S0168-9525(99)01955-1 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 8. Wegner M (1999) From head to toes: the multiple facets of Sox |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| proteins. Nucleic Acids Res 27:1409–1420. doi: 10. 1 093/nar/27.6. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 1409 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 9. Kiefer JC (2007) Back to basics: Sox genes. Dev Dyn 236:2356– |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| 2366. doi:10.1002/dvdy.21218 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 10. Lefebvre V, Dumitriu B, Penzo-Me�ndez A et al (2007) Control of |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| cell fate and differentiation by Sry-related high-mobility-group |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| box (Sox) transcription factors. Int J Biochem Cell Biol 39:2195– |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 2214. doi:10.1016/j.biocel.2007.05.019 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 11. Dong C, Wilhelm D, Koopman P (2004) Sox genes and cancer. |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Cytogenet Genome Res 105:442–447. doi:10.1159/000078217 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 12. Sohn J, Natale J, Chew LJ, Belachew S et al (2006) Identification |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| of Sox17 as a transcription factor that regulates oligoden- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| drocyte development. J Neurosci 26:9722–9735. doi:10.1523/ |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| JNEUROS CI.1716-06.2006 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 13. Matsui T, Kanai-Azuma M, Hara K et al (2006) Redundant roles |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| of Sox 17 and Sox18 in postnatal angiogenesis in mice. J Cell Sci |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 119:3513–3526. doi:10.1242/jcs.03081 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 14. Park KS, Wells JM, Zorn AM et al (2006) Sox17 influences the |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| differentiation of respiratory epithelial cells. Dev Biol 294:192– |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 202. doi:10.1016/j.ydbio.2006.02.038 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 15. Shimoda M, Kanai-Azuma M, Hara K et al (2007) Sox17 plays a |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| substantial role in late-stage differentiation of the extraembryonic |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| endodermin vitro. J Cell Sci 120:3859–3869. doi:10.1242/jcs.007856 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 16. Kim I, Saunders TL, Morrison SJ (2007) Sox17 dependence |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| distinguishes the transcriptional regulation of fetal from adult |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| hematopoietic stem cells. Cell 130:470–483. doi:10.1016/j.cell. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 2007.06.011 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 17. Jang YY, Sharkis SJ (2007) Fetal to adult stem cell transition: |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| knocking Sox17 off. Cell 130:403–404. doi:10.1016/j.cell.2007. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 07.027 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 18. Liu Y, Asakura M, Inoue H et al (2007) Sox17 is essential for the |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| specification of cardiac mesodermin embryonic stemcells. Proc Natl |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Acad Sci USA 104:3859–3864. doi:10.1073/pnas.0609100104 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 19. Sinner D, Kordich JJ, Spence JR et al (2007) Sox17 and Sox4 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| differentially regulate beta-catenin/T-cell factor activity and |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| proliferation of colon carcinoma cells. Mol Cell Biol 27:7802– |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 7815. doi:10.1128/MCB.02179-06 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 20. Zhang W, Glo�ckner SC, Guo M et al (2008) Epigenetic inacti- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| vation of the canonical Wnt antagonist SRY-box containing gene |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 17 in colorectal cancer. Cancer Res 68:2764–2772. doi: 10.1158/ |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 0008-5472.CAN-07-6349 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 21. Zorn AM, Barish GD, Williams BO et al (1999) Regulation of |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| physically interact with beta-catenin. Mol Cell 4:487–498. doi: |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 10.1016/S1097-2765(00)80200-2 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 22. Kanai-Azuma M, Kanai Y, Gad JM et al (2002) Depletion of |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| definitive gut endoderm in Sox17-null mutant mice. Development |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 129:2367–2379 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 23. de Jong J, Stoop H, Gillis AJ et al (2008) Differential expression of |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| Sox17 and SOX2 in germ cells and stem cells has biological and |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| clinical implications. J Pathol 215:21–30. doi: 10. 1002/path.2332 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 24. Morin PJ, Weeraratna AT (2003) Wnt signaling in human cancer. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Cancer Treat Res 115:169–187. doi:10.1007/0-306-48158-8_7 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 25. Karim R, Tse G, Putti T et al (2004) The significance of the Wnt |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_new bi_xmlPara_new
reference ||| pathway in the pathology of human cancers. Pathology 36:120– |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 128. doi:10.1080/00313020410001671957 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_no bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 26. Brantjes H, Barker N, van Es J et al (2002) Lady justice casting |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| the final verdict on the outcome of Wnt signalling. Biol Chem |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 383:255–261. doi:10.1515/BC.2002.027 |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 27. Li Y, Welm B, Podsypanina K et al (2003) Evidence that |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| transgenes encoding components of the Wnt signaling pathway |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| preferentially induce mammary cancers from progenitor cells. |XML| xmlLoc_0 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Proc Natl Acad Sci USA 100:15853–15858. doi:10.1073/pnas. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 2136825100 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 28. Howe LR, Brown AM (2004) Wnt signaling and breast cancer. |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| Cancer Biol Ther 3:36–41 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 29. Veeck J, Niederacher D, An H et al (2006) Aberrant methylation |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| of the Wnt antagonist SFRP1 in breast cancer is associated with |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| unfavourable prognosis. Oncogene 25:3479–3488. doi:10.1038/ |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| sj.onc.1209386 |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 30. Lo PK, Mehrotra J, D’Costa A et al (2006) Epigenetic suppres- |XML| xmlLoc_1 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| sion of secreted frizzled related protein 1 (SFRP1) expression in |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| human breast cancer. Cancer Biol Ther 5:281–286 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 31. Veeck J, Geisler C, Noetzel E et al (2008) Epigenetic inactivation |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| of the secreted frizzled-related protein-5 (SFRP5) gene in human |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| breast cancer is associated with unfavorable prognosis. Carcino- |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| genesis 29:991–998. doi:10.1093/carcin/bgn076 |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 32. Ai L, Tao Q, Zhong S et al (2006) Inactivation of Wnt inhibitory |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| factor-1 (WIF1) expression by epigenetic silencing is a common |XML| xmlLoc_2 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| event in breast cancer. Carcinogenesis 27:1341–1348. doi: |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 10.1093/carcin/bgi379 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 33. Suzuki H, Toyota M, Carraway H et al (2008) Frequent epige- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| netic inactivation of Wnt antagonist genes in breast cancer. Br J |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Cancer 98:1147–1156. doi:10.1038/sj.bjc.6604259 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 34. Akiyama H, Lyons JP, Mori-Akiyama Y et al (2004) Interactions |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| between Sox9 and beta-catenin control chondrocyte differentia- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| tion. Genes Dev 18:1072–1087. doi:10.1101/gad.1171104 |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 35. Takash W, Can˜izares J, Bonneaud N et al (2001) SOX7 tran- |XML| xmlLoc_3 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| scription factor: sequence, chromosomal localisation, expression, |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| transactivation and interference with Wnt signalling. Nucleic |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Acids Res 29:4274–4283. doi:10.1093/nar/29.21.4274 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 36. Sinner D, Rankin S, Lee M et al (2004) Sox17 and beta-catenin |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| cooperate to regulate the transcription of endodermal genes. |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Development 131:3069–3080. doi:10.1242/dev.01176 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 37. Katoh M (2002) Molecular cloning and characterization of |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| human Sox17. Int J Mol Med 9:153–157 |XML| xmlLoc_4 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 38. Feltus FA, Lee EK, Costello JF et al (2004) Predicting aberrant |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_new bi_xmlPara_new
reference ||| CpG island methylation. Proc Natl Acad Sci USA 100:12253– |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 12258. doi:10.1073/pnas.2037852100 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 39. Ushijima T (2005) Detection and interpretation of altered meth- |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| ylation patterns in cancer cells. Nat Rev Cancer 5:23–31. doi: |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 10.1038/nrc1571 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 40. Kimelman D, Xu W (2006) Beta-catenin destruction complex: |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| insights and questions from a structural perspective. Oncogene |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 25:7482–7491. doi:10.1038/sj.onc.1210055 |XML| xmlLoc_5 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 41. Lin SY, Xia W, Wang JC et al (2000) Beta-catenin, a novel |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| prognostic marker for breast cancer: its roles in cyclin D1 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| expression and cancer progression. Proc Natl Acad Sci USA |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 97:4262–4266. doi:10.1073/pnas.060025397 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 42. Turashvili G, Bouchal J, Burkadze G et al (2006) Wnt signaling |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| pathway in mammary gland development and carcinogenesis. |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Pathobiology 73:213–223. doi:10.1 1 5 9/00009 8 207 |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 43. Dolled-Filhart M, McCabe A, Giltnane J et al (2006) Quantitative |XML| xmlLoc_6 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| in situ analysis of beta-catenin expression in breast cancer shows |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| decreased expression is associated with poor outcome. Cancer |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| Res 66:5487–5494. doi:10.1158/0008-5472.CAN-06-0100 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 44. Candidus S, Bischoff P, Becker KF et al (1996) No evidence for |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| mutations in the alpha- and beta-catenin genes in human gastric |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| and breast carcinomas. Cancer Res 56:49–52 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 45. Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_new
reference ||| signalling pathway. J Cell Sci 116:2627–2634. doi:10.1242/jcs. |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue
reference ||| 00623 |XML| xmlLoc_7 xmlBold_no xmlItalic_no xmlFontSize_smaller xmlPic_no xmlTable_no xmlBullet_yes bi_xmlSFBIA_continue bi_xmlPara_continue

